Amendments to the claims:

Claims 1-2 (Cancelled)

Claim 3 (Withdrawn) The use of a $GABA_B$ receptor antagonist for the treatment of neurodegeneration

Claim 4 (Currently Amended): ~~The use of a $GABA_B$ receptor antagonist for the treatment of~~ A method for increasing neurotrophin levels in the in the central nervous system (CNS) of a patient with Parkinson's disease, amyotrophic lateral sclerosis ~~and~~, stress-induced neurodegeneration, said method comprising administering to the patient an amount of a $GABA_B$ receptor antagonist sufficient to increase neurotrophin levels in the CNS of the patient.

Claim 5 (Withdrawn) The use of a $GABA_B$ receptor antagonist for suppression of immune responses following CNS tissue grafts

Claims 6-10 (Cancelled)

Claim 11 (Withdrawn) A method for treating neurodegeneration or for suppression of immune responses following CNS tissue grafts in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a $GABA_B$ receptor antagonist.

Claim 12 (Cancelled)

Claim 13 (Withdrawn) The use according to claim 3 for increasing NGF and BDNF.

Claim 14 (Cancelled)

Claim 15 (Withdrawn) The use according to claim 5 for increasing NGF and BDNF.

Claims 16 (Cancelled)

Claim 17 (New): A method for increasing neurotrophin levels in the central nervous system (CNS) of a patient with Parkinson's disease, comprising administering to the patient an amount of a $GABA_B$ receptor antagonist sufficient to increase neurotrophin levels in the CNS of a patient with Parkinson's disease.

Claim 18 (New): A method for treating Parkinson's disease, comprising administering to the patient in need of such treatment a therapeutically effective amount of a $GABA_B$ receptor antagonist.

Claim 19 (New): The method of claim 17 wherein the antagonist is administered daily.

Claim 20 (New): The method of claim 18 wherein the antagonist is administered daily.

Claim 21 (New): The method of claim 4 wherein the $GABA_B$ receptor antagonist is selected from the group consisting of 3-{1(S)-[3-(cyclohexylmethyl)hydroxyphosphinyl)-2(S)- hydroxy-propylamino]ethyl}benzoic acid; 3-{1(R)-[3-(cyclohexylmethyl)hydroxyphosphinyl-2(S)-hydroxy-propylamino]ethyl}benzoic acid; and 3-aminopropyl-(n-butyl)-phosphinic acid.

Claim 22 (New): The method of claim 17 wherein the $GABA_B$ receptor antagonist is selected from the group consisting of 3-{1(S)-[3-(cyclohexylmethyl)hydroxyphosphinyl)-2(S)- hydroxy-propylamino]ethyl}benzoic acid; 3-{1(R)-[3-(cyclohexylmethyl)hydroxyphosphinyl-2(S)-hydroxy-propylamino]ethyl}benzoic acid; and 3-aminopropyl-(n-butyl)-phosphinic acid.

Claims 23 (New): The method of claim 18 wherein the $GABA_B$ receptor antagonist is selected from the group consisting of 3-{1(S)-[3-(cyclohexylmethyl)hydroxyphosphinyl)-2(S)- hydroxy-propylamino]ethyl}benzoic acid; 3-{1(R)-[3-(cyclohexylmethyl)hydroxyphosphinyl-2(S)-hydroxy-propylamino]ethyl}benzoic acid; and 3-aminopropyl-(n-butyl)-phosphinic acid.

Claim 24 (New): The method of Claim 4 where the $GABA_B$ receptor antagonist is administered to a patient with Parkinson's disease or amyotrophic lateral sclerosis.

Claim 25 (New): The method of Claim 23 where the $GABA_B$ receptor antagonist is administered to a patient with Parkinson's disease.

In light of the foregoing response the Applicants earnestly believe that Application is now in condition for allowance and respectfully request early notice to that effect.

If it will advance prosecution of this Application the Examiner is urged to contact the Applicants' undersigned counsel at the telephone number listed below.

Respectfully submitted,



Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7960

Edward J. Wilusz, Jr.
Attorney for Applicants
Reg. No. 52,370

Date: September 15, 2004